Pooled shRNA Screen for Reactivation of MeCP2 on the Inactive X Chromosome
March 2nd, 2018
We report a small hairpin RNA (shRNA) and next generation sequencing-based protocol for identifying regulators of X-chromosome inactivation in a murine cell line with firefly luciferase and hygromycin resistance genes fused to the methyl CpG binding protein 2 (MeCP2) gene on the inactive X chromosome.
Overview
This article presents a protocol utilizing small hairpin RNA (shRNA) and next generation sequencing to identify regulators of X-chromosome inactivation in a murine cell line. The study incorporates firefly luciferase and hygromycin resistance genes fused to the methyl CpG binding protein 2 (MeCP2) gene on the inactive X chromosome.
Key Study Components
Area of Science
- Neuroscience
- Genetics
- Cell Biology
Background
- X-chromosome inactivation is a crucial process in female mammals.
- Understanding the regulators of this process can provide insights into various genetic disorders.
- Small hairpin RNA (shRNA) is a powerful tool for gene silencing.
- Next generation sequencing allows for comprehensive analysis of gene expression.
Purpose of Study
- To develop a protocol for identifying regulators of X-chromosome inactivation.
- To utilize shRNA and next generation sequencing in a murine model.
- To investigate the role of MeCP2 in X-chromosome inactivation.
Methods Used
- Preparation of mouse tendon fibroblasts.
- Cell harvesting and trypsinization.
- Resuspension and dilution of cells for plating.
- Utilization of firefly luciferase and hygromycin resistance genes.
Main Results
- Successful identification of regulators involved in X-chromosome inactivation.
- Demonstration of the effectiveness of shRNA in gene silencing.
- Insights into the role of MeCP2 in the inactive X chromosome.
- Establishment of a reliable protocol for future studies.
Conclusions
- The developed protocol can aid in understanding X-chromosome inactivation.
- Findings may have implications for genetic research and therapies.
- Further studies are warranted to explore the identified regulators.
Frequently Asked Questions
Executive Industry Relevance
Pooled shRNA screening with reporter-based selection enables systematic identification of epigenetic regulators impacting X-chromosome inactivation, a key mechanism in mammalian gene dosage control. This approach provides predictive confidence for target validation in chromatin biology and supports risk-adjusted advancement of epigenetic drug discovery portfolios. Integration of next-generation sequencing for quantitative hit identification further enhances reproducibility and cross-functional data utility.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables functional interrogation of chromatin regulators affecting XCI using a reporter-based genetic screen.
- Supports biological de-risking by isolating shRNAs that reactivate silenced genes on the inactive X chromosome.
- Facilitates predictive confidence in target selection for epigenetic modulation strategies.
Screening & Assay Development
- Establishes a validated cell-based system for high-throughput pooled shRNA screening.
- Delivers quantitative, selection-based readouts (luciferase activity, hygromycin resistance) for robust hit identification.
- Enables scalable screening and downstream validation of candidate regulators using standardized reporter assays.
Translational & Preclinical Research
- Provides a disease-relevant system for studying XCI mechanisms with translational implications in genetic disorders.
- Supports continuity from discovery to preclinical validation by enabling functional follow-up of identified regulators.
- Offers mechanistic de-risking for epigenetic targets prior to in vivo studies.
Pipeline & Workflow Integration
This pooled shRNA screening workflow bridges early discovery and lead identification for epigenetic targets, integrating functional genomics with quantitative selection and validation.
- Discovery Biology: Supports hypothesis testing for chromatin regulator function in XCI using reporter gene reactivation.
- Screening: Provides reproducible, selection-based assays for scalable shRNA library screening.
- Analytics: Utilizes next-generation sequencing to quantitatively compare shRNA enrichment post-selection.
- Translational Research: Aligns with disease-relevant models for X-linked gene regulation studies.
- Enterprise Reuse: Establishes a platform adaptable to other epigenetic targets and screening modalities.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in chromatin target validation and reduces mechanistic ambiguity.
- Operational Value: Standardizes pooled screening and quantitative validation workflows for reproducibility.
- Strategic Value: Informs go/no-go decisions for epigenetic target advancement and portfolio prioritization.
- Portfolio Impact: Enables risk-adjusted progression of epigenetic programs with robust functional data.
Implementation Considerations
- Requires expertise in pooled shRNA library design, viral transduction, and reporter assay execution.
- Demands access to next-generation sequencing infrastructure for quantitative hit identification.
- Necessitates cross-team standardization of selection conditions and assay readouts.
- Adaptable to other cell models and reporter constructs for broader epigenetic screening.
- Dependent on robust validation of candidate hits to confirm functional relevance.
Biopharma FAQs
Chapters in this video
0:04
Title
1:17
Selecting Single Cell Clones and Characterizing MeCP2 Reporter Expression
4:31
Screening the Library for Reactivation Using Hygromycin B Selection
6:44
Validating the Identified Hairpins ( Hits )
9:27
Results: Isolation of Clones with the Reporter on the Inactive X Chromosome and Characterization of Hygromycin Resistance
10:17
Conclusion
